Fundraising Fox

MapLight Therapeutics

NASDAQ: MPLT

Redwood City, US · Founded 2018 · Delaware corporation · 2 known investors

Find your way into MapLight Therapeutics

108 people in our graph share verified history with the MapLight Therapeutics team — schools, employers, funds. One of them is your warm intro.

Chandler Lallyunlockedknows Erin Foff · together at University of Virginia (overlapped)
×6knows the team · via Thomas Jefferson University
×5knows the team · via Baylor College of Medicine

MapLight Therapeutics is a biopharmaceutical company developing targeted treatments for central nervous system disorders through a platform designed to modulate neural circuits implicated in disease. The company's lead program is a fixed-dose combination targeting muscarinic receptors in development for schizophrenia and Alzheimer's disease psychosis.

Biotech

Founders & leadership

MapLight Therapeutics was founded in 2018 by Anatol Kreitzer.

AK
Anatol KreitzerFounder
KH
Kristopher HansonExecutive
EF
Erin FoffinExecutiveErin Foff is a neurologist with expertise in cognitive neurology and clinical trial design for neurodegenerative diseases, and has spent over 15 years in basic science research on translational models of neurodegeneration.
JL
James LillieExecutive
JG
Jonathan GillisinExecutive
VSVishwas Setia
Vishwas SetiainExecutive
CA
Christopher A. KroegerPresident, Chief Executive Officer and Director
EP
Erin Pennock FoffinChief Medical OfficerNeurologist with over 15 years of experience in basic science and clinical trials, including subspecialty focus on cognitive neurology and neurodegenerative diseases. Now Chief Medical Officer at MapLight Therapeutics, a biopharmaceutical company developing targeted treatments for central nervous system disorders.
RM
Robert MalenkaNamed on SEC filing

Board

GP
George PavlovBoard director
PB
Peter BisgaardBoard director
JTJim Trenkle
Jim Trenklein𝕏Board directorInvestor at Sanofi Ventures

Investors · 2

ForbionreportedNaardenvia Nanna Luneborg · board
Novo HoldingsreportedCopenhagen · $1.1M – $54M

Funding

SEC filings, press & company announcements

$356.2M disclosed across 6 of 7 rounds · 2019–2026

  • Undisclosed amountcolocación privadaAug 2026
    Source ↗
▶$188.2MraisedJul 2025 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kristopher HansonExecutive Officer
  • Timothy GarnettDirector
  • George PavlovDirector
  • Peter BisgaardDirector
  • Erin FoffExecutive Officer
  • Anatol KreitzerExecutive Officer
  • Jim TrenkleDirector
  • James LillieExecutive Officer
  • Maria WalkerDirector
  • Christopher A KroegerExecutive Officer, Director
  • Jonathan GillisExecutive Officer
  • Vishwas SetiaExecutive Officer
  • Nanna LuneborgDirector
Offering amount
$372.4M
Amount sold
$188.2M
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$105MraisedNov 2023 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert MalenkaDirector
  • Jim TrenkleDirector
  • Peter BisgaardDirector
  • Kristopher HansonExecutive Officer
  • George PavlovDirector
  • Charmaine LykinsExecutive Officer
  • Anatol KreitzerExecutive Officer
  • Erin FoffExecutive Officer
  • Jonathan GillisExecutive Officer
  • James LillieExecutive Officer
  • Timothy GarnettDirector
  • Christopher A KroegerExecutive Officer, Director
Offering amount
$225M
Amount sold
$105M
First sale
Jul 2023
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12MraisedNov 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter BisgaardDirector
  • Christopher A KroegerExecutive Officer, Director
  • Erin FoffExecutive Officer
  • James LillieExecutive Officer
  • George PavlovDirector
  • Robert MalenkaDirector
  • Anatol KreitzerExecutive Officer
  • Jonathan GillisExecutive Officer
Offering amount
$12M
Amount sold
$12M
First sale
Oct 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30MraisedMar 2021 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher A KroegerExecutive Officer, Director
  • George PavlovDirector
  • Robert MalenkaDirector
  • Anatol KreitzerExecutive Officer
  • Peter BisgaardDirector
  • Jonathan GillisExecutive Officer
  • James LillieExecutive Officer
Offering amount
$60M
Amount sold
$30M
First sale
Feb 2021
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16MraisedSep 2019 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan GillisExecutive Officer
  • Peter BisgaardDirector
  • James LillieExecutive Officer
  • Robert MalenkaDirector
  • Christopher A KroegerExecutive Officer, Director
  • George PavlovDirector
Offering amount
$16M
Amount sold
$16M
First sale
Aug 2019
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedMar 2019 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher A KroegerExecutive Officer, Director
  • Robert MalenkaDirector
  • James LillieExecutive Officer
  • George PavlovDirector
  • Peter BisgaardDirector
  • Jonathan GillisExecutive Officer
Offering amount
$5M
Amount sold
$5M
First sale
Feb 2019
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Roundup: Pharma Funding Continues with Financing Rounds and Public Offering Price Announcements | PharmExecpharmexec.com · Aug 2026MapLight Therapeutics recauda 150 millones de dólares en colocación privada Por Investing.comes.investing.com · Aug 2026MapLight Bolsters Schizophrenia Program With New Financing Round - TipRanks.comtipranks.com · Aug 2026MapLight Therapeutics Announces Q2 2026 Financial Results with Rising Losses and R&D Expenseskalkinemedia.com · Aug 2026MapLight Raises $150 M PIPE To Fund CNS Pipelinerttnews.com · Aug 2026Intellectiaintellectia.ai · Aug 2026

Frequently asked questions

What does MapLight Therapeutics do?
MapLight Therapeutics is a biopharmaceutical company developing targeted treatments for central nervous system disorders through a platform designed to modulate neural circuits implicated in disease. The company's lead program is a fixed-dose combination targeting muscarinic receptors in development for schizophrenia and Alzheimer's disease psychosis.
Who founded MapLight Therapeutics?
MapLight Therapeutics was founded by Anatol Kreitzer in 2018.
Who are MapLight Therapeutics's investors?
MapLight Therapeutics's investors include Forbion, Novo Holdings.
How much funding has MapLight Therapeutics raised?
MapLight Therapeutics has disclosed $356.2M raised across 6 of its 7 known rounds.
Where is MapLight Therapeutics headquartered?
MapLight Therapeutics is headquartered in Redwood City, US.